The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer

Acta Medica Okayama

Volumn 66, Issue 1, 2012, Pages 53-60

  Nakamura, Keiichiro ^a   Hongo, Atsushi ^a   Kodama, Junichi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

C reactive protein; CA125; Ovarian cancer; Predictor for poor prognosis; SUVmax of primary tumor

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; C-REACTIVE PROTEIN; CA-125 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS;

EID: 84858266450     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. American Cancer Society. Cancer facts & figures 2009. Atlanta, Ga: American cancer Society, (2009).
2. Ushijima K: Current status of gynecologic cancer in Japan. J Gynecol Oncol (2009) 20: 67-71.
3. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P and Rice GE: Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol (2010) 136: 1079-1088.
4. Mironov S, Akin O, Pandit-Taskar N and Hann LE: Ovarian cancer. Radiol Clin North Am (2007) 45: 149-166.
5. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW and Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol (2010) 116: 389-394.
6. Gambhir SS: Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer (2002) 2: 683-693.
7. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST and Farias-Eisner R: The early detection of ovarian cancer: from tradi tional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol (2008) 199: 215-223.
8. Nustad K, Bast RC Jr, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Bormer OP, de Bruijn HW, et al: Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. Interna tional Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 17: 196-219.
9. Buller RE, Berman ML, Bloss JD, Manetta A and DiSaia PJ: Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol (1992) 47: 87-92.
10. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ and Høgdall CK: CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol (2007) 104: 508-515.
11. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet (2001) 357: 539-545
12. Coussens LM and Werb Z: Inflammation and cancer. Nature (2002) 420: 860-867.
13. Wang CS and Sun CF: C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J (2009)32: 471-482.
14. Nakamoto Y, Saga T, Ishimori T, Mamede M, Togashi K, Higuchi T, Mandai M, Fujii S, Sakahara H and Konishi J: Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am J Roentgenol (2001) 176: 1449-1454.
15. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L and Alavi A: Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging (2002) 29: 1639-1647.
16. Malkasian GD Jr, Melton LJ 3rd, O'Brien PC and Greene MH: Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol (1984) 149: 274-284.
17. Kalir T, Wang BY, Goldfischer M, Haber RS, Reder I, Demopoulos R, Cohen CJ and Burstein DE: Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer (2002) 94: 1078-1082.
18. Bast RC Jr, KlugTL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr and Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med (1983)309: 883-887.
19. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, Tempter CB and Reinthaller A: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian can cer. Gynecol Oncol (2006) 103: 512-517.
20. Tempter C, Zeisler H, Sliutz G, Haeusler G, Hanzal E and Kainz C: Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol (1997) 66: 27-30.
21. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H and Grimm C: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 14: 710-714.